Associated Papers
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
The role of UGT1A1 promoter polymorphism and exon-1 mutations in neonatal jaundice.
Halis H et al.
The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
[Repeated yellowing of the skin and sclera for 2 years].
Yuan XY et al.
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics, 2017
Gilbert Syndrome with Concomitant Hereditary Spherocytosis Presenting with Moderate Unconjugated Hyperbilirubinemia.
Aiso M et al.
Internal Medicine (tokyo, Japan), 2017
Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome.
Maruo Y et al.
Journal of Gastroenterology and Hepatology, 2016
Performance of In Silico Tools for the Evaluation of UGT1A1 Missense Variants.
Rodrigues C et al.
Human Mutation, 2015
Gilbert and Crigler Najjar syndromes: an update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database.
Canu G et al.
Blood Cells, Molecules & Diseases, 2013
Identification of a novel mutation in UDP-glucuronosyltransferase (UGT1A1) gene in a child with neonatal unconjugated hyperbilirubinemia.
Minucci A et al.
Clinical Biochemistry, 2013
Meta-analysis diagnostic accuracy of SNP-based pathogenicity detection tools: a case of UTG1A1 gene mutations.
Galehdari H et al.
International Journal of Molecular Epidemiology and Genetics, 2013
Regression Modeling and Meta-Analysis of Diagnostic Accuracy of SNP-Based Pathogenicity Detection Tools for UGT1A1 Gene Mutation.
Rahim F et al.
Genetics Research International, 2013
Exploring the genetic architecture of neonatal hyperbilirubinemia.
Watchko JF et al.
Seminars in Fetal & Neonatal Medicine, 2010
Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?
Strassburg CP
Drug Metabolism Reviews, 2010
Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.
Di YM et al.
The Aaps Journal, 2009
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D et al.
Cancer Treatment Reviews, 2008
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Strassburg CP et al.
Archives of Toxicology, 2008
A homozygous mutation in a Chinese man with Crigler-Najjar syndrome type II and a family genetic analysis.
Wu JX et al.
Journal of Digestive Diseases, 2008
Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).
Strassburg CP et al.
Critical Reviews in Clinical Laboratory Sciences, 2008
Cord blood bilirubin level in relation to bilirubin UDP-glucuronosyltransferase gene missense allele in Chinese neonates.
Sun G et al.
Acta Paediatrica (oslo, Norway : 1992), 2007
Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes.
Li C et al.
Bmc Evolutionary Biology, 2007
Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y et al.
Annals of the New York Academy of Sciences, 2006
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Hasegawa Y et al.
Expert Review of Molecular Diagnostics, 2006
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF et al.
Toxicology and Applied Pharmacology, 2006
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M et al.
Investigational New Drugs, 2005
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Clinical pharmacogenetics of irinotecan (CPT-11).
Ando Y et al.
Drug Metabolism Reviews, 2005
Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert's syndrome.
Sutomo R et al.
Pediatrics International : Official Journal of the Japan Pediatric Society, 2002
Correlation of mutational analysis to clinical features in Taiwanese patients with Gilbert's syndrome.
Hsieh SY et al.
The American Journal of Gastroenterology, 2001
Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.
Kadakol A et al.
Human Mutation, 2000
Intermittent jaundice in patients with acute leukaemia: a common mutation of the bilirubin uridine-diphosphate glucuronosyltransferase gene among Asians.
Kimura T et al.
Journal of Inherited Metabolic Disease, 1999
Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes.
Sampietro M et al.
Haematologica, 1999
Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese.
Akaba K et al.
Journal of Human Genetics, 1999
The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence.
Mackenzie PI et al.
Pharmacogenetics, 1997
Hematologically important mutations: bilirubin UDP-glucuronosyltransferase gene mutations in Gilbert and Crigler-Najjar syndromes.
Costa E
Blood Cells, Molecules & Diseases, 0